TriSalus Life Sciences, Inc. Share Price
Equities
TLSI
US89680M1018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +1.95% | +1.23% | -31.83% |
03/06 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
30/05 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
Sales 2024 * | 2.89Cr 240.71Cr | Sales 2025 * | 4.34Cr 361.74Cr | Capitalization | 15Cr 1.25TCr |
---|---|---|---|---|---|
Net income 2024 * | -4.6Cr -383.34Cr | Net income 2025 * | -4.4Cr -366.67Cr | EV / Sales 2024 * | 5.19 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.45 x |
P/E ratio 2024 * |
-3.1
x | P/E ratio 2025 * |
-4.24
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.5% |
Latest transcript on TriSalus Life Sciences, Inc.
1 day | +1.95% | ||
1 week | +1.23% | ||
Current month | -19.55% | ||
1 month | -27.09% | ||
3 months | -40.92% | ||
6 months | -33.64% | ||
Current year | -31.83% |
Managers | Title | Age | Since |
---|---|---|---|
Mary Szela
CEO | Chief Executive Officer | 60 | 01/18/01 |
Sean Murphy
DFI | Director of Finance/CFO | 71 | 10/23/10 |
Steven Katz
CTO | Chief Tech/Sci/R&D Officer | 49 | 10/23/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kerry Hicks
BRD | Director/Board Member | 64 | 10/23/10 |
Mats Wahlström
CHM | Chairman | 70 | 10/23/10 |
George Martin
BRD | Director/Board Member | 65 | 10/23/10 |
Date | Price | Change | Volume |
---|---|---|---|
28/24/28 | 5.52 | -4.17% | 45,743 |
27/24/27 | 5.76 | +1.95% | 16,778 |
26/24/26 | 5.65 | +1.44% | 24,262 |
25/24/25 | 5.57 | -4.30% | 30,609 |
24/24/24 | 5.82 | +2.28% | 33,364 |
End-of-day quote Nasdaq, June 27, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.83% | 15Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- TLSI Stock